Acute promyelocytic leukemia medical Interventions: Difference between revisions

Jump to navigation Jump to search
No edit summary
No edit summary
 
(7 intermediate revisions by 2 users not shown)
Line 1: Line 1:
__NOTOC__
__NOTOC__
{{Acute promyelocytic leukemia}}
{{Acute promyelocytic leukemia}}
{{CMG}}; {{AE}}, {{S.G.}}
{{CMG}}; {{AE}} {{S.G.}}; {{GRR}} {{Nat}}


==Overview==
==Overview==
There are no recommended therapeutic interventions for the management of [disease name].
The mainstay of treatment for acute promyelocytic leukemia is [[cytotoxic]] [[chemotherapy]]. Using a combination of all-trans [[retinoic acid]] and [[arsenic trioxide]] is usually reserved for patients with either relapse or resistance to further treatment.
 
OR
 
[Name of intervention] is not the first-line treatment option for patients with [disease name]. [Name of intervention] is usually reserved for patients with either [indication 1], [indication 2], and [indication 3]
 
OR
 
The mainstay of treatment for [disease name] is medical therapy/surgery. [Name of intervention] is usually reserved for patients with either [indication 1], [indication 2], and/or [indication 3].
 
OR
 
The feasibility of [name of intervention] depends on the stage of [disease or malignancy] at the time of diagnosis.
 
OR
 
[Name of intervention] is the mainstay of treatment for [disease or malignancy].


==Indications==
==Indications==
 
* The mainstay of treatment for acute promyelocytic leukemia is [[cytotoxic]] [[chemotherapy]]. Using a combination of all-trans [[retinoic acid]] and [[arsenic trioxide]] is usually reserved for patients with either relapse or resistance to further treatment.<ref name="pmid27713127">{{cite journal |vauthors=Huang J, Sun M, Wang Z, Zhang Q, Lou J, Cai Y, Chen W, Du X |title=Induction treatments for acute promyelocytic leukemia: a network meta-analysis |journal=Oncotarget |volume=7 |issue=44 |pages=71974–71986 |date=November 2016 |pmid=27713127 |pmc=5342137 |doi=10.18632/oncotarget.12451 |url=}}</ref>
The mainstay of treatment for TT is medical therapy.


==References==
==References==

Latest revision as of 13:12, 11 April 2019

Acute promyelocytic leukemia Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Acute promyelocytic leukemia from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

Other Imaging Studies

Other Diagnostic Studies

Treatment

Medical Therapy

Interventions

Surgery

Primary PreventionSurgery

Secondary PreventionSurgery

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Acute promyelocytic leukemia medical Interventions On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Acute promyelocytic leukemia medical Interventions

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Acute promyelocytic leukemia medical Interventions

CDC on Acute promyelocytic leukemia medical Interventions

Acute promyelocytic leukemia medical Interventions in the news

Blogs on Acute promyelocytic leukemia medical Interventions

Directions to Hospitals Treating Acute promyelocytic leukemia

Risk calculators and risk factors for Acute promyelocytic leukemia medical Interventions

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Sogand Goudarzi, MD [2]; Grammar Reviewer: Natalie Harpenau, B.S.[3]

Overview

The mainstay of treatment for acute promyelocytic leukemia is cytotoxic chemotherapy. Using a combination of all-trans retinoic acid and arsenic trioxide is usually reserved for patients with either relapse or resistance to further treatment.

Indications

References

  1. Huang J, Sun M, Wang Z, Zhang Q, Lou J, Cai Y, Chen W, Du X (November 2016). "Induction treatments for acute promyelocytic leukemia: a network meta-analysis". Oncotarget. 7 (44): 71974–71986. doi:10.18632/oncotarget.12451. PMC 5342137. PMID 27713127.

Template:WH Template:WS